Physician profile
Georgia Linton Stevens
NPI 1255453478
$599,575.87
in general payments reported to CMS, 2019-2025
12 companies · $114K in 2025
The $114K reported for 2025 was more than what 99% of Psychiatric/Mental Health, Adult (Registered Nurse) providers received nationally (typical 2025 total: $121).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48K · 2022: $121K · 2023: $187K · 2024: $130K · 2025: $114K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $312K · Travel and Lodging: $69K · Consulting Fee: $40K · Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $311,838.57 |
| Travel and Lodging | $68,724.54 |
| Consulting Fee | $40,103.60 |
| Food and Beverage | $10,424.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $489,938.19 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $42,179.56 | 2024-2025 | Fanapt |
| Alkermes, INC. | $26,311.91 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $19,164.21 | 2023-2024 | Invega Sustenna, Invega Trinza, Invega |
| Teva Pharmaceuticals USA, INC. | $7,673.43 | 2022-2023 | Uzedy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $6,471.71 | 2021-2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,724.74 | 2021-2024 | Abilify Asimtufii |
| H. Lundbeck A S | $2,000.00 | 2021 | |
| Lundbeck LLC | $1,857.50 | 2022-2024 | Rexulti |
| Axsome Therapeutics, INC. | $1,137.50 | 2022 | |
| Ucb, INC. | $65.00 | 2022 | |
| Jazz Pharmaceuticals INC. | $52.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georgia Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.